36. Statistics about diabetes-American diabetes association. Accessed 29th May 2020.
37. Knapp S. Diabetes and infection: is there a link? - a mini-review.Gerontology . 2013; 59: 99-104.
38. Schoen K, Horvat N, Guerreiro NFC, de Castro I, de Giassi KS. Spectrum of clinical
and radiographic findings in patients with diagnosis of H1N1 and correlation with clinical
severity. BMC Infect Dis. 2019;19(1):964.
39. Yang JK, Feng Y, Yuan MY, Yuan SY, Fu HJ, Wu BY, et al. Plasma glucose levels and
diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med. 2006;23(6):623-8.
40. Banik GR, Alqahtani AS, Booy R, Rashid H. Risk factors for severity and mortality in
patients with MERS-CoV: Analysis of publicly available data from Saudi Arabia. Virol Sin.
2016;31(1):81-4.
41. Wang A, Zhao W, Xu Z, Gu J. Timely blood glucose management for the outbreak of
2019 novel coronavirus disease (COVID-19) is urgently needed. Diabetes Res Clin Pract
2020: 108118.
42. Zhou J, Tan J. Diabetes patients with COVID-19 need better care. Metabolism
2020: 154216.
43. Iqbal A, Prince LR, Novodvorsky P, Bernjak A, Thomas MR, Birch L, et al. Effect of
Hypoglycemia on Inflammatory Responses and the Response to Low-Dose Endotoxemia in
Humans. J Clin Endocrinol Metab. 2019; 104(4):1187-99.
44. Sardu C, D’Onofrio N, Balestrieri ML, et al. Outcomes in Patients With
Hyperglycemia Affected by Covid-19: Can We Do More on Glycemic Control? Diabetes care 2020; https://doi.org/10.2337/dc20-0723
45. Honce R, Schultz-Cherry S. Impact of obesity on influenza a virus pathogenesis, immune response, and evolution. Front Immunol 2019; 10: 1071.
46. Huttunen R, Syrjänen J. Obesity and the risk and outcome of infection. Int J Obes (Lond) 2013; 37: 333-40.
47. Dixon AE, Peters U. The effect of obesity on lung function. Expert Rev Respir Med 2018; 12: 755-67.
48. Klein OL, Aviles-Santa L, Cai J, et al. Hispanics/Latinos with type 2 diabetes have functional and symptomatic pulmonary impairment Mirroring kidney microangiopathy: findings from the Hispanic community health Study/Study of Latinos (HCHS/SOL). Diabetes
Care 2016; 39: 2051-7.
49. Esler M, Esler D. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic? J Hypertension 2020; doi: 10.1097/HJH.0000000000002450.
50. Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug
Dev Res. 2020. doi: 10.1002/ddr.21656.
51. Sinclair AJ, Abdelhafiz AH. Age, frailty and diabetes – triple jeopardy for vulnerability to COVID-19 infection. EClinicalMedicine 2020; doi.org/10.1016/j.eclinm.2020.100343.